Alexandra Galati
Neurology · Honolulu, HINPI 1881048759
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,707 of the $2,045 with a category attached, or 83.5%. 17 manufacturers reported payments, led by Amgen at 32.5% of the total. 2025 is the largest year on record at $680, 2.4 times the $283 reported in 2022. That places this record below the midpoint for neurology clinicians in HI, where the typical reported total is $2,045.
Across 91 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$664
- AbbVie$508
- AstraZeneca$197
- Biogen$100
- Pfizer$99
- Bristol Myers Squibb$95
- plus $382 from 11 others
What the payments were for
- Food & beverage$1,70783%
- Education$33817%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 35 | $664 |
| AbbVie | 22 | $508 |
| AstraZeneca | 4 | $197 |
| Biogen | 4 | $100 |
| Pfizer | 5 | $99 |
| Bristol Myers Squibb | 4 | $95 |
| Sanofi | 3 | $82 |
| Novartis | 3 | $72 |
| Eisai Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| TG Therapeutics, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| SK Life Science, Inc. | 1 | $20 |
| CSL Behring | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Genentech, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$110
How this compares
$2,045 in reported general payments places this provider in the 50th percentile of 54 neurology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 20 | $210,690 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $18,965 |
| Dalfampridine ErDalfampridine | 25 | $11,112 |
| Mycophenolate Mofetil | 15 | $2,038 |
| Memantine Hcl | 47 | $1,997 |
| Levetiracetam | 61 | $1,811 |
| Gabapentin | 45 | $1,282 |
| Baclofen | 17 | $779 |
| Pregabalin | 22 | $718 |
| Topiramate | 11 | $470 |
| Duloxetine Hcl | 13 | $469 |
| Donepezil Hcl | 21 | $458 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 24 | $444 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 14 | $272 |
| Prednisone | 18 | $219 |
Paid to pharmacies, not to this prescriber.
Other neurology in Honolulu
- Leo MaherHonolulu$382K
- Leah RidgeHonolulu$47K
- Melvin YeeHonolulu$32K
- Kevin KimataHonolulu$24K
- Terry ShimamotoHonolulu$24K
- Michael RussoHonolulu$20K
- Kore LiowHonolulu$15K
- Fay GaoHonolulu$13K
- Sarah GranerHonolulu$10K
- Jeffrey LiuHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.